Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population.
COVID-19
Older adults
Vaccination
Vaccines shortage
Journal
Public health in practice (Oxford, England)
ISSN: 2666-5352
Titre abrégé: Public Health Pract (Oxf)
Pays: England
ID NLM: 101774776
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
08
03
2022
revised:
04
08
2022
accepted:
26
08
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
ppublish
Résumé
In a context of COVID-19 vaccine shortages, this study sought to evaluate the safety and efficacy of receiving one dose of Gam-COVID-Vac rAd26 followed by a second COVID-19 vaccine dose of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP-CorV in a cohort of older adults. Single-centre, randomised, open label, non-inferiority trial. Adults aged ≥65 years who had received one dose of Gam-COVID-Vac rAd26 were randomised in a 1:1:1 ratio to receive a second-dose COVID-19 vaccination of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP-CorV. The primary outcome was the assessment of the humoral immune response to vaccination (i.e. antibody titres of SARS-CoV-2 spike protein at 28 days after second-dose vaccination). In addition, neutralising antibody titres at day 28 for the three schedules were measured. Of 85 participants who were enrolled in the study between 26 and July 30, 2021, 31 individuals were randomised to receive Gam-COVID-Vac rAd5, 27 to ChAdOx1 nCoV-19 and 27 to BBIBP-CorV. The mean age of participants was 68.2 years (SD 2.9) and 49 (57.6%) were female. Participants who received Gam-COVID-Vac rAd5 and ChAdOx1 nCoV1-19 showed significantly increased anti-S titres at 28 days after second-dose vaccination, but this magnitude of difference was not observed for those who received BBIBP-CorV. The ratio between the geometric mean at day 28 and baseline within each group was 11.8 (6.98-19.89) among patients assigned to Gam-COVID-Vac rAd26/rAd5, 4.81 (2.14-10.81) for the rAd26/ChAdOx1 nCoV-19 group and 1.53 (0.74-3.20) for the rAd26/BBIBP-CorV group. All of the schedules were shown to be safe. The findings in this study contribute to the scarce information published on the safety and immunogenicity of Gam-COVID-Vac heterologous regimens and will help the development of guidelines and vaccine programme management.
Identifiants
pubmed: 36090797
doi: 10.1016/j.puhip.2022.100313
pii: S2666-5352(22)00089-1
pmc: PMC9444309
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100313Informations de copyright
© 2022 Published by Elsevier Ltd on behalf of The Royal Society for Public Health.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
JAMA Netw Open. 2021 Oct 1;4(10):e2130800
pubmed: 34714342
Hum Vaccin Immunother. 2020 Dec 1;16(12):2938-2943
pubmed: 33270497
PLoS Pathog. 2021 Jan 14;17(1):e1009161
pubmed: 33444413
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
BMJ Open. 2021 Sep 30;11(9):e049505
pubmed: 34593496
BMC Public Health. 2020 Nov 19;20(1):1742
pubmed: 33213391
Life (Basel). 2021 Mar 17;11(3):
pubmed: 33803014
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Infect Dis. 2020 Dec;101:98-101
pubmed: 32916249
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554